TRAX First Tracks Biotherapeutics
Company Analysis
Latest News
🔴 First Tracks Biotherapeutics is trading 5% down today amid broad biotech weakness
First Tracks Biotherapeutics is trading at $31.34 (-5.01%) as biotech-sector weakness coincides with the decline; no clear company-specific announcement...
🔴 First Tracks Biotherapeutics is trading 5.8% down; catalyst remains unclear
First Tracks Biotherapeutics is trading at $31.34, down 5.84%, with no clear catalyst identified. - It was down 1.89% at the October 2 close; no new company...
🟢 First Tracks Biotherapeutics is trading 5% up today
First Tracks Biotherapeutics is trading at $36.23, up 5.24%, with no confirmed company-specific announcement or catalyst dated September 28, 2026. - A...
🔴 First Tracks Biotherapeutics is trading 5.19% down today with no confirmed direct catalyst
First Tracks Biotherapeutics is trading at $33.97, down 5.19%, with no confirmed direct catalyst identified for September 25, 2026. - Recent...
🔴 First Tracks Biotherapeutics is trading 5.32% down today as rising yields and oil pressure growth stocks
First Tracks Biotherapeutics is trading 5.32% lower at $34.71, with the decline appearing mainly tied to broader risk-off trading rather than a fresh...
🔴 First Tracks Biotherapeutics is trading 10.77% down today as broad market losses pressured growth assets
First Tracks Biotherapeutics is trading 10.77% lower at $36.61 as a broad September 23, 2026 market sell-off weighed on growth-oriented assets. - The Nasdaq...
🔴 First Tracks Biotherapeutics is trading 5.4% down today amid broader market weakness
First Tracks Biotherapeutics is trading 5.4% lower at $38.80 amid broader market weakness. - On September 23, 2026, the Nasdaq Composite was down 1.05%;...
🟢 First Tracks Biotherapeutics is trading 5.5% up today amid broader biotech momentum
First Tracks Biotherapeutics is trading 5.5% up now at $41.14, with broader biotech-sector momentum the clearest explanation. - Shares rose from the September...
First Tracks Biotherapeutics earns outperform rating at Evercore, targeting immunology breakthroughs
Evercore ISI initiated coverage of First Tracks Biotherapeutics Inc. with an outperform rating. The firm established a price target of $65.00 per share for...
🟢 First Tracks Biotherapeutics is trading 6.9% up today after Guggenheim initiated coverage with a Buy rating
First Tracks Biotherapeutics is trading 6.9% up at $41.17 after Guggenheim initiated coverage with a Buy rating and a $100 price target on September 16,...
🟢 First Tracks Biotherapeutics is trading 5% up today after Guggenheim's Buy rating and $100 target
First Tracks Biotherapeutics is trading at $40.40, up +5.02%, after Guggenheim initiated coverage on September 16, 2026, with a Buy rating and a $100 price...
🟢 First Tracks Biotherapeutics is trading 5% up today; no clear catalyst identified
First Tracks Biotherapeutics is trading 5.08% up at $38.29, reversing part of its recent decline, with no clear company-specific catalyst identified. - No...
🔴 First Tracks Biotherapeutics is trading 5% down in pre-market amid broader-market weakness
First Tracks Biotherapeutics is trading at $34.50 (-5.32%) amid a weak broader-market backdrop. - No clear company-specific announcement for September 14,...
🔴 First Tracks Biotherapeutics is trading 5.95% down today — no clear company-specific announcement identified
First Tracks Biotherapeutics is trading 5.95% down now at $35.72; no clear company-specific announcement explaining the September 11, 2026 decline was...
🔴 First Tracks Biotherapeutics is trading 5% down today after hotter-than-expected PPI data
First Tracks Biotherapeutics is trading 5.21% down now at $37.51 as September 10, 2026 markets sell off following hotter-than-expected Producer Price Index...
🔴 First Tracks Biotherapeutics is trading 5% down today as Brent crude nears $100 amid regional conflict
First Tracks Biotherapeutics is trading 5.12% down now at $39.66, moving lower alongside a weak September 9, 2026 market amid elevated oil prices and Middle...
🟢 First Tracks Biotherapeutics is trading 6.38% up today — no confirmed company-specific catalyst found
First Tracks Biotherapeutics is trading $43.04, up 6.38% now, with no confirmed company-specific catalyst identified. - A Wells Fargo healthcare conference...
First Tracks Biotherapeutics downgraded to Sell, after director sheds 71% stake
Wall Street Zen downgraded First Tracks Biotherapeutics (NASDAQ:TRAX) from Hold to Sell on September 5, 2026. The rating change followed a 4.8% drop in share...
🔴 First Tracks Biotherapeutics is trading 5.8% down today — no confirmed company-specific explanation
First Tracks Biotherapeutics is trading at $42.64 (-5.83%), with no confirmed September 3, 2026 company-specific announcement explaining the decline. - Recent...
🟢 First Tracks Biotherapeutics is trading 12.22% up today
First Tracks Biotherapeutics is trading 12.22% up at $46.20, based on the provided live price context, with no confirmed catalyst identified. - No clear...